Oxford Biomedica Regulatory News (OXB)

7 Feb 2005 07:00

Oxford Biomedica PLC07 February 2005 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OFAMERICA, CANADA, AUSTRALIA OR JAPAN Oxford BioMedica plc ("Oxford BioMedica" or the "Company") Termination of discussions On 19 January 2005 the Board of Oxford BioMedica announced that it had receivedan approach from a third party regarding a potential merger, which may or maynot lead to an offer for the Company. The Board of Oxford BioMedica announces that the discussions that followed thisunsolicited approach have terminated. 7 February 2005 Enquiries: Oxford BioMedica plc Tel: +44 (0) 1865 783000Professor Alan Kingsman, Chief Executive Officer Rothschild Tel: +44 (0) 20 7280 5000Dr. Lynn Drummond N M Rothschild & Sons Limited ("Rothschild"), which is authorised and regulatedby the Financial Services Authority in the United Kingdom, acts for OxfordBioMedica plc and no one else in relation to the contents of this announcementand will not be responsible to anyone other than Oxford BioMedica plc forproviding the protections afforded to clients of Rothschild nor for providingadvice in relation to the contents of this announcement. This information is provided by RNS The company news service from the London Stock Exchange